Cancer treatment startup started by Duke faculty raises $70M

Monday, July 12, 2021
Nasdaq sign in Times Square

Nasdaq highlights Xilis on their tower in Times Square

Durham, N.C. (July 8, 2021) – Xilis, Inc., a pioneering company using its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, today announced the close of a $70 million Series A financing. The round was led by Mubadala Capital, joined by new investors GV (formerly Google Ventures), LSP (one of Europe’s largest healthcare investment firms), Catalio Ventures, Duke Endowment, and Duke Angel Network. Current investors Felicis Ventures, Two Sigma Ventures, Pear VC, KdT Ventures, and Alix Ventures also participated.

Founded in 2019 by Dr. Xiling Shen, Dr.David Hsu, and Dr. Hans Clevers, Xilis is based on decades of biomedical, oncology, and stem cell research by its three co-founders. Dr. Clevers, a Breakthrough Prize winner, is the inventor and pioneer of the organoid technology. Dr. Shen and Dr. Hsu are accomplished engineering and medical professors at Duke University and experts in precision medicine. They have developed the scalable MOS technology to analyze patients’ own tumors in their native microenvironment – a breakthrough achievement.

Read more at Duke Translation and Commercialization